Cancer Protein Makers Eye New Manufacturing Platform
A stable pool-based system could streamline XenImmune's development of tumor-targeting AGF molecules, though the assessment is still at an early stage.
Updated on Nov. 3, 2026 in Tech

XenImmune Therapeutics, based in Cambridge, Massachusetts, and GBI Biomanufacturing agreed to assess GBI's SmartScale manufacturing system for producing XenImmune's AGF protein molecules. The development is at the agreement-and-assessment stage, not a shipped manufacturing product.
Why it matters
XenImmune is developing fusion protein molecules designed to target tumors by painting cancer cell surfaces with foreign blood group sugars or antigens. The partnership reflects an effort to explore manufacturing approaches that could meet the molecules' requirements while using capital with discipline.
The announcement describes SmartScale as a stable pool-based manufacturing platform capable of delivering GMP material, but no throughput, cost, or yield figures were disclosed. Results of the assessment have not been reported.
The players
XenImmune Therapeutics
A Cambridge, Massachusetts developer of fusion protein molecules designed to target tumors.
GBI Biomanufacturing
A biomanufacturing provider offering the SmartScale stable pool-based production platform.
The details
SmartScale combines stable cell pools, deferred cloning, and single-use manufacturing. Stable cell pools are populations of cells engineered to produce a target protein consistently, while deferred cloning means individual cell lines are isolated later in development rather than at the outset. Single-use manufacturing relies on disposable plastic bioreactor bags rather than stainless-steel vessels that must be cleaned between batches. Production can be run in shake flasks or bioreactors, allowing manufacturing scale to be matched to the quantity of material needed.
Timeline
November 3, 2026: XenImmune and GBI announced the agreement to assess SmartScale.
The Tech Race
GBI positions SmartScale against the FDA's Operation TrialBlazer initiative, which the company says the platform aligns with. The extraction does not describe competing manufacturing platforms or comparative research milestones.
The agreement is an assessment, so no product or therapy is available to patients from it. Any clinical use of AGF molecules would depend on future trial results and regulatory review, neither of which has a timeline in the announcement.
The takeaway
The key trajectory signal is that biologic developers are looking beyond traditional manufacturing setups toward platforms that scale with material needs. Watch for an announced outcome of the SmartScale assessment for the AGF molecules.
Further reading
For broader context on drug manufacturing advances, see Biotech coverage across Massachusetts.
Source note: This article includes information reported by The Manila times.




